The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations

Lung, Respiratory and Thoracic Cancer

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Lancet Oncol

Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM, INSIGHT 2 investigators

doi: 10.1016/S1470-2045(24)00270-5

Lung, Respiratory and Thoracic Cancer

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Eur J Cancer

Saalfeld FC, Möller J, Christopoulos P, Wenzel C, Rasokat A, Wang XA, Vathiotis I, König D, Illini O, Grohé C, Wiesweg M, Wesseler C, Schubart C, Pelusi N, Rohde G, Overbeck TR, Kirfel J, Alt J, Kauffmann-Guerrero D, Griesinger F, Kulhavy J, Allgäuer M, Klimova A, Schütz M, Aust DE, Hochmair MJ, Rothschild SI, Syrigos KN, Veluswamy R, Michels S, Stenzinger A, Jöhrens K, Wermke M

doi: 10.1016/j.ejca.2024.115065

Lung, Respiratory and Thoracic Cancer

Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial

Lung Cancer

Liu T, He J, Wang Y, Yang Y, Zhang L, Shi M, Liu J, Sun D, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Huang Y, Fang W, Yang Y, Zhao Y, Zhang L

doi: 10.1016/j.lungcan.2025.108108

Lung, Respiratory and Thoracic Cancer

CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression

Clin Lung Cancer

Wong WKY, Mok KKS, Tsui GPC, Chen OH, Loong HHF, Chan LL, Yan K, Mo F, Lee KWC, Lam KC, Mok FST, Johnson D, Chen ACC, Lam B, Lee M, Mok TSK, Li MSC

doi: 10.1016/j.cllc.2025.01.007

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Oncol

Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, Inoue T, Rodríguez-Cid J, Zhang L, Yang CT, de la Mora Jimenez E, Zhou J, Pérol M, Lee KH, Vicente D, Ichihara E, Riely GJ, Luo Y, Chirovsky D, Pietanza MC, Bhagwati N, Lu S

doi: 10.1200/JCO.23.02747

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Barsouk A, Elghawy O, Heidlauf A, Yu C, Wang L, Yang D, Kurian M, Goel K, Rushkin L, Anran Huang A, Reed-Guy L, Bleiberg B, Sun L, Singh A, Cohen RB, Aggarwal C, Marmarelis M, Langer C

doi: 10.1016/j.lungcan.2024.107926

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer

★ 1 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

Lung Cancer

Tozuka T, Noro R, Mizutani H, Kurimoto F, Hakozaki T, Hisakane K, Naito T, Takahashi S, Taniuchi N, Yajima C, Hosomi Y, Hirose T, Minegishi Y, Okano T, Kamio K, Yamaguchi T, Seike M, East Japan Chesters Group

doi: 10.1016/j.lungcan.2024.107540

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study

★ 3 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

Ann Oncol

Lu S, Ahn MJ, Reungwetwattana T, Özgüroğlu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS

doi: 10.1016/j.annonc.2024.08.2243

Lung, Respiratory and Thoracic Cancer

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study

Eur J Cancer

Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, Pichon E, Veillon R, Gounant V, Rousseau-Bussac G, Madroszyk A, Daniel C, Ravoire M, Metivier AC, Fournel P, Missy P, Morin F, Guisier F, Westeel V

doi: 10.1016/j.ejca.2025.115301

Related content

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial

CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer

Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib

Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study